Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition and Contractual Adjustments - Narrative (Details)

v3.20.2
Revenue Recognition and Contractual Adjustments - Narrative (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
segment
Revenue from Contract with Customer [Abstract]    
Number of operating segments | segment   2
Increase in Pharma contract assets   $ 0.3
Pharma contract asset, increase (as a percent) 28.00% 28.00%
Increase in pharma contract liabilities   $ 1.4
Increase in pharma contract liabilities (as a percent)   51.00%
Pharma contract liability, revenue recognized $ 0.4 $ 1.6
Amortization of contract commissions $ 0.1 $ 0.3